Objectives. We investigated the role of endogenous endothelin-1 in the development of cardiac hypertrophy in vivo under pressure overload conditions.
Cardiac hypertrophy is a major adaptational mechanism to stresses such as pressure overload and neurohormonal stimulation. Many characteristic molecular changes have been described in association with the development of ventricular myocardial hypertrophy. Expression of immediate and early response genes is induced and there is a reappearance of "fetal" proteins such as beta-myosin heavy chain, alphaskeletal actin and atrial natriuretic peptide (10) . Because isoform distribution of myosin heavy chain is known to regulate contraction velocity and energy efficiency, much work has focused on these molecules (11) . It is well known that alphamyosin heavy chain isoform is the dominant form of myosin in the adult rat ventricular myocardium (11) , and many laboratories including this one have demonstrated the switching from alpha-to beta-myosin heavy chain isoforms that occurs during the development of cardiac hypertrophy (12) (13) (14) .
Because of the ability of endothelin-1 to regulate fundamental molecular processes in myocardial cells, we hypothesized that this peptide may be involved in the development of ventricular hypertrophy. Although several experimental in vivo models have been used to study cardiac hypertrophy induced by pressure overload, we chose the highly reproducible model of monocrotaline-induced pulmonary hypertension for these studies. Monocrotaline, a pyrrolizidine alkaloid derived from Crotalaria spectabilis, is known to cause pulmonary hypertension and fight ventricular hypertrophy by producing pulmonary vasculitis (15) (16) (17) (18) . To investigate a potential role of the endothelin-1 peptide in the development of right ventricular hypertrophy, we employed a potent and specific endothelin-A (ETA) receptor antagonist, FR139317. The pharmacologic profile of this substance on the effect of endothelin-1 has been well characterized (19) .
The use of this ETA antagonist enabled us to investigate the role of endogenous endothelin-1 in the development of ventricular hypertrophy in vivo under pressure overload conditions. FR139317 was coadministered to monocrotaline-treated rats at a dose that did not eliminate monocrotaline-induced pulmonary hypertension. Although elevated pulmonary pressures developed in rats that received FR139317, this group had a significantly smaller increase in fight ventricle/left ventricle weight ratio. Myosin heavy chain isozymic expression was evaluated as a biochemical marker of hypertrophy, and the endothelin-1 antagonist was shown to significantly decrease the appearance of beta-myosin heavy chain protein and messenger ribonudeic acid (mRNA). These data thus demonstrate that the ETA receptor antagonist FR139317 eliminates monocrotaline-induced right ventricular hypertrophy and myosin heavy chain isoform transition, and they suggest a role for endogenous endothelin-1 in the pathophysiology of this process.
Methods
Animals and physiologic studies. Twenty-nine male Wistar rats (age 4 weeks) were divided into three groups: 1) the monocrotaline group (9 rats given a single subcutaneous dose [60 mg/kg body weight] of monocrotaline) (Sigma Co. Ltd.) followed by daily subcutaneous administration of saline solution for 21 days; 2) the monocrotaline plus FR139317 group (10 rats given a single subcutaneous dose of monocrotaline followed by 10 mg/kg per day, subcutaneously, of the ETA receptor antagonist FR139317) [Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan] [19] for 21 days; and 3) the Control group (10 rats given a subcutaneous dose of monocrotaline vehicle followed by daily subcutaneous administration of saline solution for 21 days).
After 21 days, under pentobarbital sodium anesthesia (50 mg/kg), right ventricular systolic pressure was measured with a water-sealed flexible catheter through the right jugular vein and systolic arterial pressure measured through a 27-gauge needle in the carotid artery. For both measurements a physiologic transducer (Nihon Koden Co. Ltd., Tokyo, Japan) was employed. Blood samples were then taken and the rats killed. The heart was rapidly excised, the atria and great vessels were removed and the right ventricular free wall was separated. The right ventricle and the left ventricle with the septum were rinsed with ice-cold saline solution, blotted dry, weighed, frozen in liquid nitrogen and stored at -80°C.
Measurement of plasma endothelin-1 concentration. Each blood sample was placed in a chilled tube containing aprotinin (300 kallikrein-inhibiting U/ml) and ethylenediaminetetraacetic acid (2 mg/ml), and plasma was separated immediately by centrifuging at 2,000 g for 15 rain at 4°C. The plasma was stored at -80°C. Determination of plasma endothelin-1 concentration was carried out by using sandwich-enzyme immunoassay for endothelin-1 as previously described (20) . In brief, immunoreactive endothelin-1 was extracted with a Sep-pak C-18 cartridge after acidification of plasma with acetic acid, reconstituted with assay buffer and subjected to sandwichenzyme immunoassay using immobilized mouse monoclonal antibody. The detection limit of this enzyme immunoassay was 0.4 pg/ml.
Myosin heavy chain isoform analysis. Extraction of crude myosin from the myocardium was performed at 4°C with Hasselbach-Schneider solution as previously described (13), and isoforms were separated by 3.7% polyacrylamide gel electrophoresis in the presence of 20-mmol/liter sodium pyrophosphate, according to the modified method of Hob et al. (21) . The density of each band (V1, V2 and V3) was measured with a laser densitometer (Ultroscan XL, Pharmacia), and the relative amount of alpha-and beta-myosin heavy chain was calculated. The half-value of V2 density was added to those of V1 and V3.
Myosin heavy chain isoform mRNA analysis (S1 mapping analysis). Total ribonucleic acid (RNA) from the right ventricle was extracted by the acid guanidinium thiocyanate-phenolchloroform method (22) . $1 mapping analysis of myosin heavy chain mRNA was performed as previously described (13) . The complement deoxyribonucleic acid (eDNA) probe used in this study was the 3' Pst I fragment of pCMHC mini5 (beta-myosin heavy chain eDNA clone) provided by Dr. B. Nadal-Ginard (Harvard Medical School, Boston, MA) (23) . The probe was hybridized in deoxyribonucleic acid excess to -30 mg total RNA in 80% formamide for 18 h at 42°C. $1 nuclease digestion was done for 1 h, and the digestion products were separated on a 6% acrylamide and 8.3 mol/liter ureasequencing gel. The proportion of alpha-and beta-myosin heavy chain mRNA was quantitated by densitometry (UItroscan XL, Pharmacia) of the autoradiograph.
Statistical analysis. The results are expressed as mean value _+ SD. Statistical comparisons among more than three groups were carried out by using analysis of variance and the Newman-Keul test for multiple sample comparisons. Comparisons between two groups were performed by unpaired Student t test. The relative data (myosin heavy chain isozyme and mRNA) were evaluated after transformation to normal distribution of values by using the arcsine transformation (24) . In either test, a p value < 0.05 was considered statistically significant. Values for these indexes did not differ significantly in rats treated with monocrotaline or monocrotaline plus FR139317, but were significantly higher in these groups than values in control rats (p < 0.01). Data are expressed as mean value _+ SD.
Results

Hemodynamic
rats was significantly higher than that of control rats (65.0 + 16.0 vs. 32.1 _+ 7.1 mm Hg, p < 0.01). To eliminate the effect of systemic arterial pressure at the time of pressure measurement, we calculated the right ventricular systolic pressure/ aortic pressure ratio. Similarly, monocrotaline-treated rats showed a higher right ventricular systolic pressure/aortic pressure ratio than that of control rats (0.60 _+ 0.06 vs. 0.24 + 0.05, p < 0.01). The right ventricular systolic pressure and right ventricular systolic pressure/aortic pressure ratio of rats treated with monocrotaline plus FR139317 were also elevated compared with values in the control group (right ventricular systolic pressure 62.7 + 7.9 mm Hg, right ventricular systolic pressure/ aortic pressure ratio 0.60 + 0.10, p < 0.01), and there was no significant difference in these measurements between rats treated with monocrotaline or rnonocrotaline plus FR139317 (Fig. 1) . These data indicate that at the dose of 10 mg/kg per day used in this study, FR139317 had no significant effect on the elevated right heart pressures induced by monocrotaline. Pressure overload was thus equivalent in the groups treated with monocrotaline and monocrotaline plus FR139317.
Plasma endothelin-I levels. Plasma endothelin-1 concentration was significantly higher in the rats treated with monocrotaline and monocrotaline plus FR139317 (3.28 + 1.82 and 2.58 +_ 0.74 pg/ml, respectively) than in control rats (1.26 _+ 0.43 pg/ml, p < 0.01), but there was no difference between the monocrotaline and monocrotaline plus FR139317 groups.
Left and right ventrieular weight. Body weight of rats in the control group and of those treated with monocrotaline or monocrotaline plus FR139317 was 187 +_ 42, 153 _+ 21 and 158 +_ 19 g, respectively (p = NS). There was no significant difference in left ventricular weight between these three groups (0.46 _+ 0.09, 0.41 _+ 0.04, 0.46 +_ 0.06 g, respectively). Right ventricular weight was significantly higher in rats treated with (Fig. 2) . Although this ratio was also increased in rats treated with monocrotaline plus FR139317 (0.54 _+ 0.10, p < 0.01, vs. control), it was significantly lower (p < 0.01) in this group than in the group treated with monocrotaline alone. This latter difference was surprising in view of the same degree of right ventricular pressure overload in these two groups. Transition of myosin heavy chain isoform. To assess whether the ETA receptor antagonist was able to modify the hypertrophy-associated transition from the alpha-to the betamyosin heavy chain isoform, we performed pyrophosphate gel electrophoresis to analyze the cardiac myosin heavy chain isoform expression. Figure 3A shows the representative pyrophosphate gel electrophoresis of myosin extracted from the ventricles of rats in the control and treated groups. Three bands, V1 (as), V2 (a/3) and V3 (/3/3), were visible in monocrotaline-treated rats, whereas only one band (V1) was visible in control rats. Although three bands were also visible in the tissue samples from rats treated with monocrotaline plus FR139317, the intensity of the V3 band was weaker than that seen with those treated with monocrotaline alone.
The proportion of beta-myosin heavy chain in right ventricular myocardium was greater in monocrotaline-treated than in control rats (lane 2, monocrotaline group 0.21 +-0.01 vs. lane 1, control group 0.03 _+ 0.03, p < 0.01) (Fig. 3B) . However, rats treated with monocrotaline plus FR139317 showed significantly lower ratios of beta-myosin heavy chain (0.08 _+ 0.04) than did rats treated with monocrotaline alone (lane 2 vs. showing the relative ratio of beta-rnyosin heavy chain isoform in control rats (n = 10) and rats receiving rnonocrotaline (n = 9) or monocrotaline plus FR139317 (n = 10). Although the proportion of beta-rnyosin heavy chain in the two groups receiving monocrotaline was significantly higher (p < 0.0i) than that in the control group, it was also lower (p < 0.01) in rats receiving rnonocrotaline plus FR139317 than in rats receiving rnonocrotaline alone. Data are expressed as mean value _+ SD. Abbreviations as in Figure 1 .
transition of alpha-to beta-myosin heavy chain isoforms in the right ventricle was induced during the development of monocrotaline-induced hypertrophy, and the ETA receptor antagonist partially inhibited this transition. Transition of myosin heavy chain mRNA. We next examined whether these changes in the relative ratio of alpha-and beta-myosin heavy chain proteins reflected corresponding changes at the mRNA level. The relative levels of mRNAs coding for the alpha-and beta-myosin heavy chain were quantitated by S1 nuclease mapping. Figure 4A shows a representative S1 mapping analysis of the alpha-and betamyosin heavy chain mRNAs. Figure 4B shows quantitative composite data reflecting the proportion of beta-myosin heavy chain to total myosin heavy chain mRNA for the three experimental groups. In the control rats the alpha-myosin heavy chain mRNA was predominant, and in monocrotalinetreated rats the beta-myosin heavy chain mRNA was predominant. This finding was reflected in a significant difference in the proportion of beta-myosin heavy chain between the two groups (lane 2, monocrotaline group 0.63 _+ 0.27 vs. lane 1, Figure 4 . Myosin heavy chain (MHC) isoform messenger ribonucleic acid (mRNA) distribution of right ventricular myocardium in the three groups of rats. A, Representative pattern of S1 mapping analysis of myosin heavy chain isoforrn mRNA. B, Bar graph showing the relative ratio of beta-rnyosin heavy chain isoforrn mRNA in the control rats (n = 10) and rats receiving monocrotaline (n = 9) and rnonocrotaline plus FR139317 (n = 10). Although the proportion of beta-myosin heavy chain rnRNA was significantly higher (p < 0.01) in rats receiving monocrotaline or monocrotaline plus FR139317 than in control rats, it was significantly lower (p < 0.025) in rats receiving monocrotaline plus FR139317 than in rats receiving rnonocrotaline alone. Data are expressed as mean value _+ SD. Abbreviations as in Figure l. control group 0.03 + 0.02, p < 0.01). Although the alphamyosin heavy chain mRNA was detected in samples from rats treated with monocrotaline plus FR139317, the proportion of beta-myosin heavy chain was significantly lower than that of rats treated with monocrotaline alone (lane 2, monocrotaline group 0.63 -+ 0.27 vs. lane 3, monocrotaline plus FR139317 group 0.33 -+ 0.23, p < 0.025).
Discussion
Right ventricular hypertrophy induced by pressure overload and the role of endothelin-l. In this study, we investigated the role of endogenous endothelin-1 on the development of anatomic and molecular characteristics of cardiac hypertrophy. This was studied by administration of a receptor antagonist specific for the ETA receptor during the development of right ventricular pressure overload resulting from monocrotalineinduced pulmonary vascular disease. This model system was chosen because of its reproducibility and because the left ventricle remains unaffected and left ventricular pressures and anatomy can serve as internal controls. As expected, monocrotaline alone produced right ventricular hypertrophy associated with elevated pulmonary artery pressures. Although administration of the receptor antagonist did not significantly blunt the pressure response, it did significantly block the hypertrophic response to the pressure increase. Miyauchi et al. (25) showed that another ETA receptor antagonist, BQ123, prevented development of right ventricular hypertrophy while also preventing pulmonary hypertension. However, they used a higher daily dose of ETA receptor antagonist than the dose of FR139317 we used. Recently, Ito et al. (26) reported that BQ123 blocked left ventricular hypertrophy in an aortic banding model. Taken together, these data obtained with very different models of ventricular hypertrophy and employing different ETA antagonists provide a compelling argument that endothelin-1 is involved in the pathophysiology of the hypertrophic response.
To determine whether the ETA receptor antagonist could alter the molecular program associated with the myocardial response to increased pressure, we evaluated the myosin heavy chain isoform pattern in the experimental and control rats. Monocrotaline-treated rats developed the characteristic alphato beta-myosin heavy chain isoform transition, as documented by both protein and mRNA studies. FR139317 was shown to inhibit the myosin heavy chain isoform switch. These data thus suggest that the ETA receptor antagonist inhibits the molecular program that directs or is associated with the anatomic changes of hypertrophy.
Endothelin-1 signal transduction system in myocardial cells. In vascular smooth muscle cells, endothelin-1 acts through its specific ETA receptor, and signals from this receptor stimulate phosphatidyl inositol production, activate protein kinase C and lead to vascular smooth muscle cell contraction and growth (27). Recently, exogenous endothelin-1 was shown (7, 9) to induce phosphatidyl inositol response, protein kinase C activation and cardiac gene expression in myocardial ceils in culture. Protein kinase C activation has been linked to cardiac hypertrophy. It has been described that angiotensin II and mechanical stretch induce cardiac gene expression and myocardial cell growth through the protein kinase C pathway (28) (29) (30) (31) (32) . Also, up-regulation of betamyosin heavy chain gene expression by alpha-adrenergic receptor stimulation has been shown (33) (34) (35) to involve protein kinase C. If endothelin-1 is directly involved in the pathogenesis of hypertrophy, as implied from our receptor antagonist data, it would seem most likely to result from protein kinase C activation. This possible role of protein kinase C in the endothelin-l-induced cellular changes associated with elevated ventricular pressures will be directly addressed experimentally in future studies.
Plasma endothelin-1 levels were elevated in monocrotalinetreated rats, but these levels did not differ between rats treated with monocrotaline and monocrotaline plus FR139317. The elevated endothelin-1 levels in the rats in which hypertrophy developed is consistent with a role for endothelin-1 in this process. These findings may reflect the increased local expression of endothelin-1, as prepro endothelin-1 mRNA in the heart has been shown (25) to be increased in monocrotalinetreated rats. These data are consistent with a functional role for endothelin-1 as a paracrine or autocrine factor in the development of cardiac hypertrophy in vivo.
Clinical implications, Findings reported here and in the recent work by Ito et al. (26) have important implications for the treatment of clinical cardiac hypertrophy. In recent years, the role of the local cardiac renin-angiotensin system in the development of cardiac hypertrophy has been intensively studied (36) . Clinical trials (37, 38) have shown the beneficial effects of angiotensin-converting enzyme inhibitors, which are able to inhibit cardiac hypertrophy and improve the prognosis of patients with congestive heart failure. Very recently, clinical trials of angiotensin II receptor antagonists in patients with heart failure (39) have also been reported. In a similar fashion, blocking the action of endogenous endothelin-1 at the myocardial cells with an ETA receptor antagonist may provide an additional treatment for cardiac hypertrophy.
Summary. In summary, ETA receptor antagonist prevents the transition of myosin heavy chain isoform and regresses the right ventricular hypertrophy in rats with monocrotalineinduced pulmonary hypertension without changing the pressure loading condition. These data demonstrate that endogenous endothelin-1 contributes to the progression of cardiac hypertrophy independent of the pressure overload in vivo.
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